Hearing manufacturers react to Eli Lilly's hearing therapy foray
On Tuesday, the US-based company announced the acquisition of hearing loss gene therapy developer – but hearing firms Demant, GN Hearing, and WSA aren’t concerned.
by albert rønning-andersson, translated by daniel pedersen
On Tuesday, Eli Lilly announced its intention to acquire Boston-based Akouos for potentially as much as USD 610m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sensorion initiates study of hearing loss therapy candidate
For subscribers
